Antiplatelet and Anticoagulation Usage During Ultrasound-Guided Incisionless Thread Carpal Tunnel Release.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 39976134.
- Also identified by DOI 10.1177/15589447251317237 and PMC identifier 11843562.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Carpal tunnel syndrome (CTS) is the most common peripheral nerve entrapment syndrome. The thread carpal tunnel release (TCTR) is an incision-less ultrasound-guided approach to divide the transverse carpal ligament. This retrospective case series aims to identify and assess the bleeding risks associated with continuing anticoagulation or antiplatelet therapy during TCTR. Retrospective chart review with follow-up questionnaires/surveys. One hundred and fourteen adult patients who were using antiplatelet or anticoagulation medication underwent 164 TCTR procedures during 2018 to 2023 at a single institution (tertiary care hospital) from June 29, 2018, and August 11, 2023. A chart review was performed to identify patients on antiplatelets or anticoagulants at the time of the procedure and to determine if there were any adverse events associated with continuing or holding their antiplatelet or anticoagulant therapy. There were no significant complications associated with continuing or holding anticoagulation or antiplatelet therapy during TCTR. Continuing antiplatelet therapy during TCTR appears safe. The decision to continue antiplatelet or anticoagulation therapy should be made on a case-by-case basis.
Medical subject headings
- Carpal Tunnel Syndrome
- Anticoagulants
- Platelet Aggregation Inhibitors
- Ultrasonography, Interventional
Anatomy
- wrist
- hand